Home Tags Enhertu

Tag: Enhertu

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Trastuzumab Deruxtecan Shows Clinically Meaningful Survival Across Multiple HER2 Expressing...

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial (ClinicalTrials.gov Identifier: NCT04482309) * confirms that trastuzumab deruxtecan ([fam-trastuzumab deruxtecan-nxki in the U.S. only] Enhertu®; Daiichi Sankyo and AstraZeneca) continues to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple human epidermal growth factor receptor 2 (HER2) expressing advanced solid tumors.

ESMO 2023: ADCs Taking Center Stage

During the annual ESMO 2023 Congress, organized by the European Society for Medical Oncology, held October 20 - 24, 2023 in Madrid, Spain, antibody-drug conjugates or ADCs took center stage, with presentations demonstrating the potential these ADCs show in the rapidly changing treatment landscape for various cancers.

Trastuzumab Deruxtecan Offers an Effective Treatment Option for Patients with Difficult-to-treat...

Trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca; previously known as DS-8201a) is an effective treatment option for patients diagnosed with difficult-to-treat HER2-expressing solid tumors.

World ADC 2023 London – What to Expect

With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...

Sacituzumab Govitecan Expected to Become Gilead’s Blockbuster Following Expanded Approval

In early February this year, the U.S. Food and Drug Administration (FDA) approved  sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with...

Trastuzumab Deruxtecan Demonstrates Clinical Activity in Neoadjuvant Setting in Patients with...

Patients diagnosed with hormone receptor-positive (HR+)/HER2-negative breast cancer frequently experience disease response to neoadjuvant therapy. However, following standard chemotherapy or endocrine therapy, even in combination with CDK4/6...

Trastuzumab Deruxtecan Shows Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously...

Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...

Gilles Gallant, BPharm, PhD, FOPQ, Receives the 2022 George R. Pettit...

Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer, at Mythic Therapeutics has received the George R. Pettit Individual Input to the Field Award for 2022.  The award was presented at the 13th World ADC Conference, held in San Diego, CA, during the 9th World ADC Awards Ceremony held on Thursday, September 8, 2022.

US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC

The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...

Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...

X